LOS ANGELES BUSINESS JOURNAL PRESENTS

PATRICK SOON-SHIONG

INNOVATION AWARDS
I n It's no secret that Los Angeles is the greatest city in the world for innovation and dreamers converting brilliant ideas into valuable, game-changing real-world products, services, and businesses. As long-time and supporters of hometown innovation here at the Los Angeles Business Journal, it's my distinct honor and privilege to present the annual Patrick Soon-Shiong Innovation Awards and Symposium for 2016.

It's certainly among the most exciting and meaningful events that we present each year – as it should be, with innovation and creativity being, after all, what sparks the economic competitiveness of the region and a distinct and unique edge to our local economy.

Truly, a personification of innovation, Dr. Soon-Shiong himself has more than led by example. He's a brilliant entrepreneur who has repeatedly illustrated how creative, groundbreaking thinking can drive economic value while improving – even saving – lives. Moreover, he shares our desire to acknowledge and encourage his fellow innovators and has once again made the commitment to underwrite this prestigious award program.

This year, the awards were handed out at a ceremony on November 17th at the Four Seasons Hotel in Beverly Hills, where we were also excited to host a half-day symposium that began with breakfast and progress through a series of several terrific guest speakers. Our attendees had an opportunity to be inspired by local innovators sharing their expertise on generating some of the great ideas coming out of California. The evening portion of the event was highlighted by the Patrick Soon-Shiong Innovation Awards dinner, where we honored and acknowledged the people and organizations that continue to stretch the boundaries and have proven to be leaders in innovation.

Thanks to Dr. Soon-Shiong and the other terrific minds that played a role in helping us select our honorees from a pool of fascinating and inspirational finalists.

Congratulations to this year’s extraordinary honorees and exceptional finalists – each of whom continues to inspire us and provide invaluable contributions to keeping Los Angeles at the forefront of innovation.

Matthew A. Toledo
President and Publisher

Dr. Patrick Soon-Shiong and Business Journal publisher Matt Toledo

DR. PATRICK SOON-SHIONG, INNOVATOR

D r. Patrick Soon-Shiong knows as well as anyone that innovation, coupled with passion and hard work, is the engine for success in business – not to mention a catalyst for life enhancing, or even life-saving activity.

His groundbreaking concepts for curing diabetes led to the first nanotechnology-based breast cancer drug, Abraxane, which is credited with saving thousands of lives. He’s since made time to research personalized drug therapies based on people’s gene sets, one of the hottest trends in research.

Now, for the sixth year, his love of innovation has prompted him to once again join the Business Journal in handing out Patrick Soon-Shiong Innovation Awards to deserving organizations that may in fact remind Soon-Shiong a little bit of his own early stages as a passionate entrepreneur and innovator.

We created this very special awards program to showcase Los Angeles as a place of innovation for businesses – and innovation in business nearly always leads to growth.

Here’s a closer look at the inspiration and namesake of our innovation award, Dr. Patrick Soon-Shiong.

Dr. Soon-Shiong is a physician, surgeon and scientist, who pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 170 issued patents worldwide on groundbreaking advancements spanning myriad fields of technology and medicine.

Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization and Chairman and CEO of NantKwest, a Nasdaq listed immunotherapy company focusing on Natural Killer cells. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, and a visiting Professor at the Imperial College of London and Dartmouth College. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award, he was the Ellis Island Medal of Honor Award Recipient, and the recipient of the Giddens Club New York City Award for the Advancement of Cancer Medicine.

In 2016 he launched Cancer Moonshot 2020 a coalition of biotech, pharma, academia, community oncologists, payers and government agencies committed to accelerating next generation sequencing, proteomics, big data analytics and immunotherapy drug development for all cancer types.

Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. The drug is approved in the U.S. and EU for metastatic breast cancer, lung cancer and advanced pancreatic cancer, making it the only drug of its kind to be approved in first line therapies across this broad spectrum of tumors in both the US and EU.

From 1997 to 2010 Dr. Soon-Shiong has served as founder, Chairman and CEO of two global pharmaceutical companies, American Pharmaceutical Partners and Abraxis BioScience. Both were acquired for multi-billion dollars in 2008 and 2010. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network. In 2015 he initiated the public offering of NantKwest, setting a record when trading opened on Nasdaq as the largest biotech IPO by market cap in history. In 2016, he received the Franklin Bower Award for Business Leadership from The Franklin Institute.

Letter from the Publisher
CONGRATULATIONS TO

CloudBreak Health
KeraMed, Inc.
Scorpion Computer Services, Inc.
SolarReserve
Transient Plasma Systems, Inc.

ON RECEIVING THE
2016 PATRICK SOON-SHIONG INNOVATION AWARD
The CloudBreak Health story starts with the company forming as Language Access Network in 2003 and soon becoming the pioneer of the medical Video Remote Interpretation industry providing interpretation services to Limited English Proficient and Deaf and Hard-of-Hearing patients. Currently, the organization has the largest number of language offerings in the industry.

CloudBreak Health was formed by bringing together two industry leaders, Language Access Network (the leading Video Remote Interpreting pioneering healthcare) and Carenection (the first Telemedicine market network) to deliver unified telehealth solutions to hospitals nationwide.

It was realized that, with the huge private HIPAA compliant network that CloudBreak created and had in place for years in over 500 hospitals nationwide, the company indeed had an already-built system to easily integrate telemedicine offerings and could offer both Language Services and Telemedicine services with the touch of one button.

CloudBreak believes that hospitals should not need multiple platforms for multiple specialties and that each specialty should be available in a care team approach on a single platform. For example, if a hospital has a Spanish-speaking patient that requires a tele-psych consult as well as an interpreter, CloudBreak’s innovative system has that need covered at the push of a button.

This is accomplished by using CloudBreak’s Carenection Telemedicine Delivery Network (one of the nation’s first and largest private path broadband network optimized for telehealth) to connect clients to the company’s Telehealth Marketplace where CloudBreak has partnered with industry leading providers of telemedicine. Thanks to this innovative system, CloudBreak is currently performing over 60,000 encounters per month at over 500 hospitals on this platform, which now makes CloudBreak’s the most used telemedicine system in country.

The implications for how CloudBreak is solving healthcare disparities and providing support for population health are broad reaching. Its clients can become both a consumer and provider of telemedicine services.
THE PRIVATE BANKING AND INVESTMENT GROUP AT MERRILL LYNCH SALUTES THE PATRICK SOON-SHIONG INNOVATION AWARDS, RECOGNIZING INNOVATION AND ENTREPRENEURSHIP

The Private Banking and Investment Group at Merrill Lynch is committed to supporting individuals and organizations in our community that contribute to enhancing the neighborhoods where we live. Life’s better when we’re connected®

The Gray Group
Eric Gray
Managing Director – Wealth Management
Private Wealth Advisor
310.407.3979 • eric_gray@ml.com

Merrill Lynch Private Banking and Investment Group
2049 Century Park East
Suite 1100
Los Angeles, CA 90067
KeraMed, Inc. has developed the first non-penetrating artificial cornea that can be used to treat 90% of the causes of corneal blindness worldwide. Unlike artificial corneas that are available today, KeraMed’s unique device can be implanted in the office of a general ophthalmologist or a corneal transplant surgeon instead of an operating room.

The company was founded in 2005 to enable the treatment of the 10 million people worldwide with cornea blindness that currently cannot receive a corneal transplant. KeraMed has developed the KeraKlear artificial cornea, the first artificial cornea that can address the dual problems of a lack of donor tissue and a lack of corneal transplant surgeons. The KeraKlear artificial cornea has European CE mark approval and has been used successfully in Europe, South America, Canada and Japan.

The KeraKlear can be implanted through a micro-incision of about 3.5 mm into the cornea without the use of sutures. This enables a new procedure that is much less invasive because the incision size is only 1/7th of that normally used for transplantation. Moreover, only about 5% of the corneal volume is removed for implantation. The KeraMed procedure also does not require entry into the interior of the eye, which greatly reduces the risk of serious complications. Because the KeraMed artificial cornea does not require donor tissue, this technology enables treatment for most of the 99% of 10 million cornea blind people in the world who currently do not have access to donor tissue. Five-year data has shown that the retention rate of the device is approximately 90%, which is comparable to the success rate for corneal transplantation.

The availability of cornea transplant tissue is limited to about 100,000 per year because of the paucity of human donors. This means that 99% of the 10 million bilaterally blind cornea patients worldwide cannot receive any treatment. KeraMed is able to manufacture an unlimited number of artificial corneas to address this need.
JAKKS Pacific Proudly Supports the Dr. Patrick Soon-Shiong Innovation Awards that Further Innovation and Entrepreneurship

Congratulations to the Winners & Finalists
SCORPION COMPUTER SERVICES, INC.

Burbank

Corpion Computer Services' ScenGen is an award-winning software program that generates all possible scenarios for any given situation at a very high speed. ScenGen has proven useful to the U.S. Navy and Air Force in both testing systems and real-time mission planning.

Scorpion Computer Services is the real-life company founded by Walter O'Brien whose life story inspired the CBS television show "Scorpion." Team Scorpion was designed to provide solutions for "any funded problem" and for 30 years now it has provided intelligence on demand as a concierge service from a network of world-class experts to solve problems big and small.

One of the team of innovators' greatest accomplishments is the aforementioned ScenGen. ScenGen is a "Scenario Generator" and one of Scorpion's latest and most profound artificial intelligence inventions. ScenGen extends a human's ability to think of all possibilities for any given situation by over ten-fold. ScenGen has broad applicability but is most commonly used to exhaustively "think of" and then "execute" all user actions or systems messages as tests on all new releases of your software. This ensures that every new release is no worse (i.e. does not regress) than the current production version.

This technology has been proven to scale in some of the world's largest companies within the most complex of environments to eliminate issues with new releases that would otherwise cause damage, downtime or misinformation such as memory exceptions, memory leaks, crashes, failed installations, etc.

In an operational setting, where, for example, a military task force works toward examining all possibilities for a given problem, ScenGen's AI generates 250 years of human thinking every 90 minutes, so a project manager or commander can be certain that all possible scenarios for a given situation have been considered.
NantStudio

8601 Hayden Place
Culver City, CA

www.NantStudio.com

PRE-LIT
360 GREEN SCREEN

FULLY EQUIPPED
MOTION CAPTURE

IDEAL FOR
VIRTUAL PRODUCTION,
FILM, TV, & PHOTOSHOOTS

LARGEST SMART STAGE IN LOS ANGELES
SolarReserve has worked to develop and integrate a first of its kind technology, making it possible to store energy generated from the sun at a large scale. By turning the sun into a 24/7 energy source, SolarReserve offers a clean solution that can meet the growing global need for reliable, electric power that is dispatchable around the clock and is a viable cost-effective alternative to baseload coal, nuclear or natural gas burning electricity generation facilities. Both in the ability to store and in affordability, SolarReserve has successfully addressed the key issues the renewable industry faces today.

SolarReserve’s unique and innovative technology uses tracking mirrors called heliostats that follow the sun throughout the day and reflect and concentrate sunlight onto a large heat exchanger called a receiver that sits atop a central tower. Within the receiver, molten salt flows through piping that forms the external walls, absorbing the heat from the concentrated sunlight. After passing through the receiver, the high temperature molten salt is then passed through a steam generation system to produce high quality superheated steam which then drives a standard steam turbine at a maximum efficiency, generating a firm supply of zero emission, truly green electricity.

This storage technology has been successfully employed and is in operation at SolarReserve’s flagship Crescent Dunes project in Tonopah, Nevada, a $1 billion utility-scale solar power plant with fully integrated energy storage, enabling day and night operation — the first of its kind to exist. In November 2015, Crescent Dunes passed the necessary tests to reach commercial operation and now delivers 110 megawatts of electricity plus 1,100 megawatt hours of energy storage to Nevada, under a 25-year power purchase agreement with NV Energy. The energy storage capability at Crescent Dunes is equal to all the world’s utility scale batteries in operation today, combined — at a fraction of the cost.

Kevin Smith of SolarReserve
“I feel very fortunate with First Republic – they make banking an enjoyable process.”

SHAHIN GHADIR, M.D.
Founding Partner, Southern California Reproductive Center
MOST people living in metropolitan areas will interact with Transient Plasma Systems (TPS) technology every day of their lives by 2025. TPS makes and sells a proprietary platform technology based on nanosecond electrical pulse science that enables transformational impact on large and growing market segments in energy, transportation, medical, and agricultural industries. In addition to demonstrated improvements in fuel efficiency in engines and reduced emissions, a wide array of other demonstrated applications of nanosecond pulses include exhaust remediation, drag reduction in aircraft wings by more than 30 percent, improved wine quality and quantity and reduced maturation time after its application to wine grapes, microbial disinfection and a noninvasive cancer treatment that leaves no scars.

TPS has been profitable since its first sale from a garage in Southern California in 2009, selling laboratory bench devices to research institutions and aerospace companies exploring the many applications of its core technology. The company is a spinout from Prof. Martin Gundersen’s world renowned Pulsed Power Group at USC, where the founding team’s miniaturization breakthroughs lead to the formation of the company.

The largest target market for TPS’ advanced ignition system is new passenger cars. Even while electric cars increase in popularity, the automobile industry will remain dominated by gasoline engines for the foreseeable future, which are forecast to remain at levels above 50% market share through 2050. Over 16 million new vehicles with internal combustion engines are sold each year in the U.S. alone, so even small advances in fuel economy will have a significant impact on the health, economy, and environment.

TPS’ patented technology, validated by OEMs and national laboratories and reported in numerous peer reviewed publications is potentially the only solution that meets all requirements for manufacturers, including significantly improved fuel economy through extended dilute-burn capability, plug & play replacement, and reduced vehicle component wear.
DERMSPECTRA, LLC

Chula Vista

DERMSPECTRA, has developed an innovative high-resolution standardized full body imaging system designed to aid early detection of skin cancers and diseases, and revolutionizes medical skin imaging. The DermSpectra Automated Full Body Digital Skin Imaging (DSI) System fills a key technology gap in medical imaging, empowers physicians and patients with an objective tool to precisely and efficiently detect and track skin and body changes over time and raising the bar on patient care.

The DermSpectra Total Body Digital Skin Imaging System is a proprietary solution that delivers patented high-resolution imaging, secure storage, and immediate viewing capabilities. With the most advanced level of precision in the market, DermSpectra sets the industry standard (definition, timing, lighting, image quality, data formats, secure storage, and interfaces) in digital skin imaging for dermatologists, plastic surgeons, cancer centers, clinical trials, general practitioners, and telemedicine services. The DermSpectra Total Body Digital Skin Imaging System solution strives to improve early detection of melanomas, skin cancers and treatment outcomes for patients and physicians by providing skin images that enable a comprehensive view and comparison of skin lesions and body changes over time.

Traditional skin photography is an underutilized technology in dermatology and general practitioners due to the large time commitment and expense incurred by patients (getting imaged by a medical photographer) and physicians (reviewing individual body part photos) along with uncontrolled image capture and inadequate centralized. DermSpectra has developed three components, 1) 10 minute automated nine camera full body high resolution (36.3 MP) standardized imaging booth, 2) with a HIPAA compliant storage and image management system, and 3) an efficient viewing application for physicians to annotate images and save to the EMR, all of which will increase the adoption and utilization of imaging, image management and data access as a tool for tracking skin changes over time.

Aptly named, Inspire is building the world’s most consumer-centric clean energy utility, and inspiring a connected movement of modern consumers towards a brighter energy future.

In short, Inspire is leveraging cloud based technologies and big data analytics to revolutionize a century old industry through whole-home solutions. Inspire’s goal is straightforward – to help consumers make choices about the way they live that are good for the environment, increase their home value, and make sense for their wallet. The way the company is effectively managing to attain that goal is through innovation.

Inspire’s inaugural product offering, a frictionless clean energy subscription, enables consumers to run their home on 100% wind power in less than 5 minutes. In addition to wind power, Inspire provides home performance insights, smart technology recommendations, and a world-class member experience. At maturity, Inspire expects to build and develop its own utility scale solar assets, which would make it the world’s first vertically-integrated 100% clean energy utility.

Put simply, Inspire’s vision is to build the utility of the future - a consumer first, vertically integrated clean tech platform positioned to drive a massive movement of consumers towards a brighter energy future.
MAKING THE SMARTPHONE MORE INTELLIGENT.

From a UCLA lab in October 1969, a computer scientist sent the very first internet message, and changed the world forever. Today, fueled by the same boundless ingenuity, Bruins are inventing more accurate ways to diagnose cancer. Creating synthetic biofuels. And, in the case of alumnus Adam Cheyer, giving the smartphone a voice. A co-founder of Siri, Inc., Cheyer helped transform artificial intelligence into a practical, everyday tool. Not only changing how we embrace technology, but how technology embraces us.

WHAT WILL YOU REIMAGINE?

UCLA.edu/optimists
Bhavin Parikh of Magoosh

As the demand for high test scores has grown, admission to top colleges and grad schools has become almost unattainable for those who can't afford expensive prep classes and tutors.

Magoosh is changing that by offering affordable and accessible test prep on web and mobile so that students can study at their own pace and on their own time — regardless of location, social status, or background.

Magoosh provides innovative online test prep for the GRE, GMAT, LSAT, SAT, ACT, TOEFL, and Praxis. The company offers unique study tools on web and mobile so that students can learn at their own pace, wherever they are, for a fraction of the cost of traditional test prep.

It started in 2009, when Magoosh CEO Bhavin Parikh and a few of his classmates at UC Berkeley’s Haas School of Business bonded over their common disappointment in the test prep industry: why should anyone have to spend well over $1,000 on GMAT classes? And wasn’t the cost just raising the barrier of entry to higher education for millions of students?

So, they got together and came up with Magoosh, an online test-prep startup designed to level the playing field by making prep for the GRE, GMAT, LSAT, SAT, ACT, TOEFL, and Praxis available and affordable.

Magoosh now proudly serves more than 1.5 million students around the world on web and mobile. The system tracks each student’s progress. That way, students know exactly what areas they're excelling in and which ones they need to work on, therefore optimizing their study time and providing the personal attention they may not find in traditional classes.

Tom Blair of Iteris

Iteris® is the global leader in applied informatics for transportation and agriculture, turning big data into big breakthrough solutions. The company collects, aggregates, and analyzes data on traffic, roads, weather, water, soil, and crops to generate precise informatics that lead to safer transportation and smarter farming.

Informed by the science of collecting, aggregating, and analyzing big data and then presenting contextually relevant insights — particularly for engineers, scientists, and technologists — to make better decisions and achieve better solutions to big global problems. With more devices and the internet of things generating more and more data, and with Iteris’ extraordinary capability to process, analyze, and machine learn from that data, the company is applying informatics to help society gain insights into the dynamics of highly complex systems to better manage them. Its products and services analyze more than 1.6TB of data every day to help make smarter decisions in two massive industries under enormous pressure to modernize: the $620 billion global transportation infrastructure market and the $5 trillion dollar global agriculture market.

Iteris was nominated this year for its ClearAg Mobile application that launched in the App Store earlier this year. ClearAg Mobile puts data science and analytics to work for growers, agribusiness, and agri-food service providers -- making farming more sustainable and productive. Using a proprietary land surface model of the entire planet combined with decades of weather data as well as soil and plant data, ClearAg Mobile can predict soil moisture and optimize plant health and growth with big data-driven advice on when to plant, water, fertilize, treat and harvest crops anywhere in the world.

Bhavin Parikh of Magoosh
Congratulations to all of the finalists and winners of the Patrick Soon Shiong Innovation Awards.

www.wsgr.com
QT Medical Inc.

Torrance-based QT Medical has designed the first electrocardiogram (ECG) for newborns that will be used for screening for long QT syndrome—a cause for SIDS. In the process, the company has essentially re-invented the ECG and will completely change the way ECG’s are done, where they are done and who will do the tests.

Currently, there is no 12-lead ECG available for home use. Long QT syndrome occurs in 1 in 2000 babies and can cause sudden death (SIDS—4 million babies in the U.S. each year are at risk and need ECG screening). There are other significant needs for ECG home use. For example, sudden cardiac arrest kills 100-200 young athletes per year. 10 million athletes in U.S. need ECG screening each year. 10 million patients with chronic heart failure, or after CABG/stent, will benefit from home ECG monitoring.

With the wide acceptance of mobile and wearable technologies, the ECG industry is at a critical point of transformation. QT Medical is making hospital quality 12-lead ECG available to patients at home, which is a game-changer for the industry and the process.

The first product is a compact, full function 12-lead ECG for home use, called QT Screen. The company will launch QT Screen services for long QT syndrome screening in infants in Q1 of 2017. The QT Screen services will roll out in California first, then gradually expand to other states. The second product, QT ECG, is a wireless, digital 12-lead ECG that uses mobile devices and is managed in the cloud. The company plans to launch the QT ECG product and services to the nursing home market in Q2 of 2017, which will bring significant values to the nursing homes by providing an easy-to-use ECG system, clinical interpretation, and cloud management that saves 80% time and 30% cost.

Ritter Pharmaceuticals

Ritter Pharmaceuticals is pioneering research in the gut microbiome. Its lead therapeutic, RP-G28, is a late-stage pharmaceutical drug that has the potential to be the first FDA-approved treatment for lactose intolerance.

Ritter is in phase 2b/3 development of the therapeutic, which is a novel and innovative treatment for the drastically overlooked patient population of lactose intolerance sufferers. There are currently over one billion people globally that are lactose intolerant and over 40 million in the U.S. alone. The current options for patients are very limited and consist of lactase supplements, dairy free products, and avoiding dairy. These options are inconvenient for patients and not always reliable.

Co-founder Andrew Ritter suffered from severe lactose intolerance starting at age 9. Doctors reported there was no solution: either avoid dairy, or endure the symptoms. Frustrated and bothered by his lactose intolerance, in the 8th grade Ritter set out to seek a better treatment for his condition. He conducted in-depth research and consulted with leading national experts such as W. Allan Walker at Harvard Medical School. With their guidance and the knowledge he gathered, Ritter used himself as the first trial subject to formulate, test, and develop a treatment for lactose intolerance. The result was a product that, taken over thirty days, adapts the digestive system to digest dairy foods. The efficacy of the product broke new research ground by altering the human microbiome and established a theory the medical community had not thought possible for gastrointestinal treatments.

With his own personal affliction with lactose intolerance in mind, and the millions of others suffering from lactose intolerance, Ritter went on to found Ritter Pharmaceuticals with the mission to produce the first FDA approved prescription treatment for lactose intolerance and advance research into the human microbiome. Today, Ritter Pharmaceuticals is a leading research and development company conducting cutting edge research in the microbiome.
UCLA Smart Grid Energy Research Center, Los Angeles

UCLA Smart Grid Energy Research Center (SMERC), has demonstrated a range of technologies to enable the development of the next generation of the electric grid. SMERC is currently working on the topics of Electric Vehicle Integration (G2V and V2G), Automated Demand Response (ADR), Microgrids, Distributed and Renewable Integration, and Energy Storage Integration.

The Center’s WINSmartGrid Technology brings together the logical components of EdgeWare, Middleware and Centralware to create a flexible Smart Grid architecture for electric vehicles.

WINSmartEV is a smart, grid-friendly, garage-friendly and user-friendly research platform being developed in UCLA that allows plug-in devices or "EVSmartPlugs," to perform remote monitoring and control of EV charging through a smart communications network. These edge-of-the-network EV plug-in devices in UCLA collect critical data including energy consumption and various power-quality related variables and upload the data to a centralized database controlled by a database server. The WINSmartEV Research Network monitors the charging, schedules optimized aggregated charging sequences, and executes the schedule via the control network. The approach is also able to incorporate market and demand considerations into the scheduling of charging. WINSmartEV has about 1.5 years of research data collected on the UCLA campus.

The charging stations used in the WINSmartEV network are designed and manufactured by SMERC. These charging stations are compatible with SAE J1772 standard. Each SMERC charging station are equipped with smart meters, microcontroller, gateway and 4 charging outlets which can provide charging services to 4 PEVs at the same time. SMERC charging stations are able to change charging current when there is utility demand response request. Optimal charging scheduling is performed in these charging stations with the control from control center. Up to now there are already 217 SMERC charging stations installed in various public parking lots in UCLA campus, downtown LA, Santa Monica, Long Beach and Pomona.
PATRICK SOON-SHIONG INNOVATION AWARDS 2016

NOMINEES

24Hr HomeCare
AirMap
Appetize, LLC
ASTRAEA THERAPEUTICS LLC
ATOMS Movie, LLC
BEZALEL
BioAlta, LLC
Bringhub
CalAsia Pharmaceuticals, Inc. (DBA: Plex Pharmaceuticals)
Califa Farms
California Safe Soil, LLC
Claremont Lincoln University
Cloudbreak Health
Collaborative Drug Discovery
Corent Technology, Inc.
Crown & Lantern
DermSpectra, LLC
dotstudioPRO
Edmunds
Elevate My Brand
Elysium Therapeutics, Inc.
Enervee
Enplug, Inc.
Everipedia, Inc.
FabFiFun
Factual
Financial Finesse, Inc.
Fishermen Labs
Fluency Lighting Technologies, Inc.
GeneFluidics
GRID Logistics, Inc.
HAWKE MEDIA
HazAwayToday.com
Heal
HG Data
HomeHero
HONK Technologies
HopSkipDrive
ImmpORT Therapeutics Inc dba Antigen Discovery, Inc.
Inspire
International Technologies and Services, Inc.
Itiris
ITex Group
KeraMed Inc.
Kite Pharma
LA County Business Federation (BizFed)
Larta Institute
Laurel & Wolf
Loaf Crate
Lucky Day Entertainment, Inc.
Magoosh
MakersKit
Mend
Nano Hydrophobics, Inc.
Neon Roots
NextGen Crowdfunding, LLC
OmegaTurf, Inc.
Omnin Nano
Onciomed, Inc
Open Listings Co
Oryn Therapeutics
Pick My Solar
QT Medical, Inc.
R+Expert DOJO
RealtyMogul.com
Replicated
Ritter Pharmaceuticals
Science Inc
Scorpion Computer Services, Inc.
Sidebench
SkyH2O, Inc.
SolarReserve
Soylent
Spinal Singularity, Inc.
St. Jude Medical
Stratio, Inc.
Sustainable Desal, LLC
Swenson He
The Albright
The Leukemia & Lymphoma Society
Torrey Hills Technologies, LLC
Transient Plasma Systems, Inc.
Twenty20
UCLA Smart Grid Energy Research Center
United Angel Investors TV
ValueScape Analytics, Inc.
Vator, Inc.
Velas Biosystems
WaiveCar
WhizGirls Academy and Play-Werks

A Breakthrough Technology
Aids in Early Skin Cancer Detection

Introducing DermSpectra™ -
The first total body imaging system that documents critical skin changes with standardized, high-definition photography, easy-iPad viewing, and image management.

- High quality, repeatable full body clinical photographs of patients
- Imaging in less than 10 minutes - safe, secure and private
- Easy iPad interface with immediate viewing for diagnosis and monitoring
- HIPAA compliant image management, secure data and PDF attaches to EMR
- Images used for telederm and referrals
- Fits in a standard dermatologist’s office, with desktop or tablet interface

Know the Skin You’re In
Quick, Easy Financing Available*

Call 800-610-2079 or visit dermspectra.com to learn more!

*With approved credit. Prices are subject to change without notice. DermSpectra is a trademark of DermSpectra, LLC.
PATRICK SOON-SHIONG INNOVATION AWARDS 2016

EVENT SCENE

1. Walter O’Brien (Scorpion); 2. Patrick Maloney (Inspire); 3. Yang Ping Pan and Ruey-Kang Chang (QT Medical); 4. James B. Edwards (Cloudbreak Health); 5. Andrew Ritter (Ritter Pharmaceuticals); 6. Dr. Mitchell Kline (Dermspectra, LLC); 7. Karleen Seybold (Dermspectra, LLC); 8. Dr. Rajit Gadh (UCLA Smart Grid Research Center); 9. Ruey-Kang Chang (QT Medical); 10. Tom Blair (Iteris); 11. Guest of Event; 12. Dr. Yichieh Shiuey (KeraMed Inc.); 13. Dan Singleton (Transient Plasma Systems); 14. Desiree Doubrox (Empowered Women); 15. Kevin Smith (SolarReserve)
PATRICK SOON-SHIONG INNOVATION AWARDS 2016

EVENT SCENE

PATRICK SOON-SHIONG INNOVATION AWARDS 2016

(1) Sonia Panikh (EY); (2) Patrick Soon-Shiong, Kevin Smith (SolarReserve) and Eric Gray (Merrill Lynch); (3) Susan Kim (Rodriguez, Horii, Choi & Cafferata); (4) Ruey-Kang Chang (QT Medical); (5) Jakks Pacific Team; (6) Karleen Seybold, Jillian Seybold and Grace Seybold and team (Dermspectra, LLC); (7) Patrick Soon-Shiong; (8) Andrew Kircher and Patrick Maloney (Inspire); (9) Kevin Smith (SolarReserve); (10) Sara Rosales Montahoa (Jakks Pacific); (11) Drew Madarsh and team (Biren); (12) CloudBreak Health representative and Eric Gray (Merrill Lynch)